Latest News
Search News
Vitamin B5 could improve red blood cell production in people with myelodysplastic syndromes
2nd March 2023
Scientists from Barts Cancer Institute at Queen Mary University of London and the Francis Crick Institute, have uncovered why patients with a rare type of blood cancer suffer from ineffective red blood cell production, and how vitamin B5 could be combined with existing drugs to improve outcomes.
Read more
Introducing Dr Özgen Deniz
21st December 2022
We are pleased to welcome Dr Özgen Deniz to Barts Cancer Institute (BCI) at Queen Mary University of London as a Lecturer and Group Leader. After receiving a Cancer Research UK Career Development Fellowship, Dr Deniz is establishing her own independent research group in BCI’s Centre for Haemato-Oncology.
Read more
BCI researcher part of Strategic Collaboration Agreement with Queen Mary, Envisagenics and Cancer Research Horizons
14th December 2022
BCI’s Dr Ana Rio-Machin is part of a new research collaboration agreement that will leverage Envisagenics’ SpliceCore® AI platform for expanded discovery and research in haematopoietic cancers.
Read more
Research on the use of urine biomarkers for early detection of pancreatic cancer
28th November 2022
Professor Tatjana Crnogorac-Jurcevic and her team at Barts Cancer Institute, Queen Mary University of London, are working to identify biological clues or ‘biomarkers’ for early, non-invasive detection of pancreatic cancer in urine samples. In their most recent paper, published in the International Journal of Cancer, the team reported that a urine biomarker panel could detect pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer, up to 2 years before clinical diagnosis.
Read more
Research identifies new way to halt pancreatic cancer invasion by targeting healthy cells
10th November 2022
Researchers from Barts Cancer Institute at Queen Mary University of London have identified a new channel of communication through which non-cancerous cells drive the invasion of cancer cells in pancreatic cancer. By blocking a particular signalling molecule within this pathway, called Fibroblast Growth Factor Receptor 1, the team was able to reduce invasion of pancreatic cancer cells in the laboratory.
Read more
Professor Fran Balkwill named in top 100 female scientists in the UK
4th November 2022
On 21 October, Research.com released its first annual ranking of top female scientists in the world and Professor Fran Balkwill from Barts Cancer Institute, Queen Mary University of London, has been named as one of the top 100 female scientists in the UK. The aim of the ranking is to “inspire female scholars, women considering an academic career, as well as decision-makers worldwide with the example of successful women in the scientific community.”
Read more